-
Opicapone as First-Line Adjunctive Levodopa Treatment in Parkinson’s Disease Patients with Motor Fluctuations: Findings from BIPARK-I and II Combined Post-Hoc Analysis
-
Opicapone in Clinical Practice in Parkinson’s Disease Patients with Motor Fluctuations: Findings from the OPTIPARK Study
-
Opicapone in fluctuating Parkinson’s disease: The daily clinical practice
-
Opicapone in Parkinson’s disease – a centre’s real-life experience
-
Opicapone management: A 2-year follow up real- life practice study
-
Opicapone study in daily clinical practice. OPRA study
-
Opicapone’s added benefit as a first-line adjunctive therapy to levodopa and when used promptly in the motor fluctuations spectrum of Parkinson’s disease: a post-hoc analysis of BIPARK-I and II
-
Optic atrophy and parkinsonism in a family associated with OPA1 mutation
-
Oral treatment of the SOD1G93A transgenic mouse model of amyotrophic lateral sclerosis (ALS) with the neuro-inflammation inhibiting compound PRI-003
-
Oral Venglustat in Parkinson’s Disease Patients With a GBA Mutation: Study Design of Part 2 of the MOVES-PD Trial and Patient Characteristics
- « Previous Page
- 1
- …
- 96
- 97
- 98
- 99
- 100
- …
- 149
- Next Page »